Nautilus Q1 net loss narrows 12% to $14.7 million; R&D expense falls 16% to $9.7 million

• Nautilus Biotechnology posted a net loss of USD 14.7 million for Q1 2026, narrowing 12%.
• Revenue remained at no revenue.
• Total operating expenses fell 14% to USD 16.12 million.
• Cash, cash equivalents and short-term investments totaled USD 95.9 million as of March 31, 2026.
• Iterative Mapping Early Access Program launched in January 2026 with Tau service offerings, with pre-orders expected to open in late 2026 and first instrument installations targeted for early 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nautilus Biotechnology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001808805-26-000022), on April 28, 2026, and is solely responsible for the information contained therein.